The ordinary shares were offered at a price of USD 19 per share and the pre-funded warrants at a price of USD 18,9999 per pre-funded warrant. With full exercise of the over-allotment option on closing, the offering results in gross proceeds for NewAmsterdam of approximately USD 200 million.
Next to Paul and Nina Kielman (lead tax partner) the team consisted of Marloes van der Laan, Eline van Marle, Joppe Schoute and Daan Hagelstein.
About NewAmsterdam
NewAmsterdam (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to provide transformational therapies for patients suffering from a range of diseases where abnormal cholesterol metabolism remains a significant cause of morbidity and mortality despite treatment with existing standards of care. They are developing safe, convenient, oral metabolic therapies to help change the treatment paradigm for these patients.